In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micromet Inc.

Division of Amgen Inc.
www.micromet.com

Latest From Micromet Inc.

Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray

Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
M & A Business Strategies

TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.

Financing ImmunoOncology

Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic

The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.

Research and Development Strategies Cancer

R&D Head Sean Harper On Amgen's Long-Term Investment View

Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Micromet AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Patrick A Baeuerle, PhD, SVP, CSO
    Jan Fagerberg, MD, PhD, SVP, CMO
    Joseph Lobacki, Chief Commercial Officer
  • Contact Info
  • Micromet Inc.
    Phone: (240) 752-1420
    9201 Corp. Blvd.
    Ste. 400
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register